{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068546","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.869874+00:00","generated_at":"2026-05-22T00:14:44.859002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025","bullets":["Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.","Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.","TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.","Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.","TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068546","json":"https://secwatch.observer/filing/0000950170-25-068546.json","markdown":"https://secwatch.observer/filing/0000950170-25-068546.md","text":"https://secwatch.observer/filing/0000950170-25-068546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/0000950170-25-068546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:14:44.859002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}